New Developments in Chronic Kidney Disease Treatments
Disc Medicine, Inc. (NASDAQ:IRON), a forward-thinking biopharmaceutical company dedicated to addressing serious hematologic conditions, has exciting news to share from the 2024 American Society of Nephrology (ASN) Kidney Week. The company will unveil significant new clinical data related to its candidate drug DISC-0974, specifically targeting patients impacted by chronic kidney disease (CKD) and associated anemia.
Presentation at ASN Kidney Week
The conference, an important event for researchers and healthcare professionals in the nephrology field, is scheduled to take place in sunny San Diego. During this gathering, Disc Medicine intends to present findings from a Phase 1b study that explores the safety and efficacy of DISC-0974. This study is particularly focused on non-dialysis dependent chronic kidney disease patients who experience anemia.
Study Insights
The recent presentation will delve into safety and pharmacokinetics associated with DISC-0974, alongside its effects on hepcidin, iron levels, and anemia. As noted by John Quisel, the company's President and CEO, sharing these new data highlights their commitment to developing treatments that address the urgent needs of patients with CKD.
Details of the Presentation
Anticipation is building with the upcoming presentation, which has been assigned Abstract Number: 4126178. The study is described as a double-blind, placebo-controlled investigation into DISC-0974’s efficacy among the targeted demographic. The event is set for October 25, during the hours of 10:00 AM to 12:00 PM PST, with presentations led by Dr. Pablo Pergola.
About DISC-0974
DISC-0974 functions as an anti-hemojuvelin antibody, a groundbreaking approach to modulating iron metabolism within the body. By targeting hepcidin regulation, DISC-0974 represents a potential shift in how anemia related to CKD can be managed, thereby improving patient quality of life.
Research Goals and Future Directions
Disc Medicine's ongoing research endeavors are focused on creating innovative therapies that can positively impact hematologic health. By capitalizing on unique biological pathways related to red blood cell development and iron management, the company aims to introduce first-in-class therapeutics capable of alleviating serious conditions faced by many patients.
Commitment to Patients
With their eyes set on the future, the team at Disc Medicine is passionate about meeting patient needs and addressing the complexities of hematologic diseases. Engaging in trials like the one for DISC-0974 reflects their staunch commitment to scientific advancement and patient-centered care.
Frequently Asked Questions
What is DISC-0974 used for?
DISC-0974 is being investigated as a treatment for anemia associated with non-dialysis dependent chronic kidney disease.
When is the presentation of the data?
The presentation will occur on October 25, between 10:00 AM and 12:00 PM PST at the ASN Kidney Week conference.
Who is presenting the data?
The data will be presented by Dr. Pablo Pergola, a key figure in the research conducted on DISC-0974.
What type of study is being presented?
The study is a Phase 1b, double-blind, placebo-controlled trial focusing on the safety and pharmacokinetics of DISC-0974.
How does Disc Medicine aim to make a difference?
Disc Medicine is dedicated to discovering and developing novel treatments through an understanding of crucial biological pathways associated with red blood cell biology and iron homeostasis.
